Report Summary
Eternity Insights has published a new study on Global Fibromyalgia Drugs Market focusing on key segments as by Type (Serotonin Norepinephrine Reuptake Inhibitors, GABA Analogs, Other), by Application (Hospitals, Clinics, Other), and by region. This deep dive re-search report highlights the market and competitive intelligence across the key segments of the mar-ket. The report also considers the impact of COVID-19 on the global Fibromyalgia Drugs Market.
The report considers 2018-2020 as historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the market drivers, challenges, and trends to accurately map the market scenario and competition. Moreover, key insights related to market having direct impact on the market will also be covered.
Fibromyalgia Drugs Market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
Global Fibromyalgia Drugs Market Size, 2018-2028 (USD Million)
To learn more about this report
Global Fibromyalgia Drugs Market Segmentation:
Fibromyalgia Drugs Market, By Type
- Serotonin Norepinephrine Reuptake Inhibitors
- GABA Analogs
- Other
Fibromyalgia Drugs Market, By Application
To learn more about this report
Geographically, the market is categorized in to five regions as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region dominates the global Fibromyalgia Drugs market in terms of demand generation. The Fibromyalgia Drugs market in Asia Pacific region is expected to grow at significantly high growth rate. The regional market is further sub-segmented and analyzed at granular level across key countries. The report will include market size and forecast for Fibromyalgia Drugs market for below listed coun-tries across each region.
North America (U.S. and Canada), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific region); Latin America (Brazil, Mexico, and rest of the Latin America); Middle East and Africa (GCC, South Africa, and Rest of the Middle East and Africa).
Global Fibromyalgia Drugs Market Taxonomy:
To learn more about this report
Global Fibromyalgia Drugs Market Competitive Landscape
The global Fibromyalgia Drugs market analysis report covers detailed analysis of competitive scenario across globe. The report includes profiles of leading players covering below details
- Company Overview
- Financial Analysis
- Product Portfolio Analysis
- Strategic Overview
- SWOT Analysis
List of Companies Profiled in the report:
- Pfizer
- Eli Lilly
- Actavis
- Merck Sharp and Dohme
- Daiichi Sankyo
- Innovative Med Concepts
- Meda
- Meiji Seika
- Switch Biotech
- Theravance
- Zynerba Pharmaceuticals
- Tonix Pharmaceuticals Holding Corp. (TNXP)
- Other Players of Specific Interest can be added based on requirement
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Serotonin Norepinephrine Reuptake Inhibitors, GABA Analogs, Other |
| By Application Outlook |
Hospitals, Clinics, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, Innovative Med Concepts, Meda, Meiji Seika, Switch Biotech, Theravance, Zynerba Pharmaceuticals, Tonix Pharmaceuticals Holding Corp. (TNXP) |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Benefits to the stake holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
Table Of Contents
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Fibromyalgia Drugs Market Size Growth Rate by Type (2017-2027)
1.4.2 Serotonin Norepinephrine Reuptake Inhibitors
1.4.3 GABA Analogs
1.4.4 Other
1.5 Market by Application
1.5.1 Global Fibromyalgia Drugs Market Share by Application (2017-2027)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Fibromyalgia Drugs Market Size
2.2 Fibromyalgia Drugs Growth Trends by Regions
2.2.1 Fibromyalgia Drugs Market Size by Regions (2017-2027)
2.2.2 Fibromyalgia Drugs Market Share by Regions (2017-2020)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Fibromyalgia Drugs Market Size by Manufacturers
3.1.1 Global Fibromyalgia Drugs Revenue by Manufacturers (2017-2020)
3.1.2 Global Fibromyalgia Drugs Revenue Market Share by Manufacturers (2017-2020)
3.1.3 Global Fibromyalgia Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Fibromyalgia Drugs Key Players Head office and Area Served
3.3 Key Players Fibromyalgia Drugs Product/Solution/Service
3.4 Date of Enter into Fibromyalgia Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Fibromyalgia Drugs Market Size by Type (2017-2020)
4.2 Global Fibromyalgia Drugs Market Size by Application (2017-2020)
5 United States
5.1 United States Fibromyalgia Drugs Market Size (2017-2020)
5.2 Fibromyalgia Drugs Key Players in United States
5.3 United States Fibromyalgia Drugs Market Size by Type
5.4 United States Fibromyalgia Drugs Market Size by Application
6 Europe
6.1 Europe Fibromyalgia Drugs Market Size (2017-2020)
6.2 Fibromyalgia Drugs Key Players in Europe
6.3 Europe Fibromyalgia Drugs Market Size by Type
6.4 Europe Fibromyalgia Drugs Market Size by Application
7 China
7.1 China Fibromyalgia Drugs Market Size (2017-2020)
7.2 Fibromyalgia Drugs Key Players in China
7.3 China Fibromyalgia Drugs Market Size by Type
7.4 China Fibromyalgia Drugs Market Size by Application
8 Japan
8.1 Japan Fibromyalgia Drugs Market Size (2017-2020)
8.2 Fibromyalgia Drugs Key Players in Japan
8.3 Japan Fibromyalgia Drugs Market Size by Type
8.4 Japan Fibromyalgia Drugs Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Fibromyalgia Drugs Market Size (2017-2020)
9.2 Fibromyalgia Drugs Key Players in Southeast Asia
9.3 Southeast Asia Fibromyalgia Drugs Market Size by Type
9.4 Southeast Asia Fibromyalgia Drugs Market Size by Application
10 India
10.1 India Fibromyalgia Drugs Market Size (2017-2020)
10.2 Fibromyalgia Drugs Key Players in India
10.3 India Fibromyalgia Drugs Market Size by Type
10.4 India Fibromyalgia Drugs Market Size by Application
11 Central & South America
11.1 Central & South America Fibromyalgia Drugs Market Size (2017-2020)
11.2 Fibromyalgia Drugs Key Players in Central & South America
11.3 Central & South America Fibromyalgia Drugs Market Size by Type
11.4 Central & South America Fibromyalgia Drugs Market Size by Application
12 International Players Profiles
12.1 Pfizer
12.1.1 Pfizer Company Details
12.1.2 Company Description and Business Overview
12.1.3 Fibromyalgia Drugs Introduction
12.1.4 Pfizer Revenue in Fibromyalgia Drugs Business (2017-2020)
12.1.5 Pfizer Recent Development
12.2 Eli Lilly
12.2.1 Eli Lilly Company Details
12.2.2 Company Description and Business Overview
12.2.3 Fibromyalgia Drugs Introduction
12.2.4 Eli Lilly Revenue in Fibromyalgia Drugs Business (2017-2020)
12.2.5 Eli Lilly Recent Development
12.3 Actavis
12.3.1 Actavis Company Details
12.3.2 Company Description and Business Overview
12.3.3 Fibromyalgia Drugs Introduction
12.3.4 Actavis Revenue in Fibromyalgia Drugs Business (2017-2020)
12.3.5 Actavis Recent Development
12.4 Merck Sharp and Dohme
12.4.1 Merck Sharp and Dohme Company Details
12.4.2 Company Description and Business Overview
12.4.3 Fibromyalgia Drugs Introduction
12.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Drugs Business (2017-2020)
12.4.5 Merck Sharp and Dohme Recent Development
12.5 Daiichi Sankyo
12.5.1 Daiichi Sankyo Company Details
12.5.2 Company Description and Business Overview
12.5.3 Fibromyalgia Drugs Introduction
12.5.4 Daiichi Sankyo Revenue in Fibromyalgia Drugs Business (2017-2020)
12.5.5 Daiichi Sankyo Recent Development
12.6 Innovative Med Concepts
12.6.1 Innovative Med Concepts Company Details
12.6.2 Company Description and Business Overview
12.6.3 Fibromyalgia Drugs Introduction
12.6.4 Innovative Med Concepts Revenue in Fibromyalgia Drugs Business (2017-2020)
12.6.5 Innovative Med Concepts Recent Development
12.7 Meda
12.7.1 Meda Company Details
12.7.2 Company Description and Business Overview
12.7.3 Fibromyalgia Drugs Introduction
12.7.4 Meda Revenue in Fibromyalgia Drugs Business (2017-2020)
12.7.5 Meda Recent Development
12.8 Meiji Seika
12.8.1 Meiji Seika Company Details
12.8.2 Company Description and Business Overview
12.8.3 Fibromyalgia Drugs Introduction
12.8.4 Meiji Seika Revenue in Fibromyalgia Drugs Business (2017-2020)
12.8.5 Meiji Seika Recent Development
12.9 Switch Biotech
12.9.1 Switch Biotech Company Details
12.9.2 Company Description and Business Overview
12.9.3 Fibromyalgia Drugs Introduction
12.9.4 Switch Biotech Revenue in Fibromyalgia Drugs Business (2017-2020)
12.9.5 Switch Biotech Recent Development
12.10 Theravance
12.10.1 Theravance Company Details
12.10.2 Company Description and Business Overview
12.10.3 Fibromyalgia Drugs Introduction
12.10.4 Theravance Revenue in Fibromyalgia Drugs Business (2017-2020)
12.10.5 Theravance Recent Development
12.11 Zynerba Pharmaceuticals
12.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
13 Market Forecast 2021-2027
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2021-2027)
13.10 Market Size Forecast by Application (2021-2027)
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
